Impact of Biopsy Proven Liver Fibrosis on Patients Undergoing Evaluation and Treatment for Advanced Heart Failure Surgical Therapies

There is a paucity of data regarding the impact of liver fibrosis on patients with stage D heart failure (HF). We conducted a retrospective study (January 1, 2017 to December 12, 2020) in patients with stage D HF who underwent liver biopsy as part of their advanced HF therapy evaluation. Baseline ch...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2023-05, Vol.194, p.46-55
Main Authors: Goyal, Amandeep, Dalia, Tarun, Ranka, Sagar, Sauer, Andrew J., Hu, Jinxiang, Cernik, Colin, Nuqali, Abdulelah, Chandler, Jonathan, Parimi, Nikhil, Dennis, Katie, Majmundar, Monil, Tayeb, Taher, Haglund, Jennifer, Shah, Zubair, Vidic, Andrija, Gupta, Bhanu, Haglund, Nicholas A.
Format: Article
Language:English
Subjects:
Biopsy
Cardiac catheterization
Congestive heart failure
Creatinine
Diabetes
Fibrosis
Heart Failure
Heart transplantation
Heart-Assist Devices
Hemodynamics
Hepatitis
Hepatology
Humans
Hypertension
Intubation
Laboratories
Liver
Liver cirrhosis
Liver Cirrhosis - complications
Liver diseases
Mortality
Patients
Retrospective Studies
Review boards
Software
Subgroups
Transplantation
Transplants & implants
Ultrasonic imaging
Ventricle
Ventricular assist devices
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a paucity of data regarding the impact of liver fibrosis on patients with stage D heart failure (HF). We conducted a retrospective study (January 1, 2017 to December 12, 2020) in patients with stage D HF who underwent liver biopsy as part of their advanced HF therapy evaluation. Baseline characteristics and 1-year outcomes were compared between no- or mild-to-moderate–fibrosis (grade 0 to 2) and advanced-fibrosis (grade 3 to 4) groups. Of 519 patients with stage D HF, 136 who underwent liver biopsy (113 [83%] no or mild-to-moderate fibrosis and 23 [17%] advanced fibrosis) were included. A total of 71 patients (52%) received advanced HF therapies (23 heart transplantation, 48 left ventricular assist devices). One-year mortality was higher among patients with advanced fibrosis (52% vs 18%, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2023.02.004